The kidney has a rich blood supply, a significant transporter activity, and acts as a highly structured filtration network. These characteristics may result in exposure of the kidneys to high concentrations of drugs or metabolites, ultimately increasing their susceptibility to drug-induced toxicity. Due to the incidence of drug-induced nephrotoxicity, it is important to understand the risks of this liability before reaching the clinic.
A cell-based in vitro assay will be of great value for drug discovery programs, as screening and structure-activity relationship can be studied in an easier and more costly manner. This assay can counter-screen the kidney toxicity of multiple drug candidates, allowing for simultaneous optimization of on-target efficacy and reduction of off-target effects.
A variety of in vitro models are available at Creative Bioarray, including isolated fragments (glomeruli and tubular fragments), primary cultured cells, continuous cell lines, and cell-free systems. These in vitro nephrotoxicity models provide a reliable tool for safety evaluation in the early stages of drug discovery.
The nephrotoxicity assay provides a mean to measure renal dysfunction due to the toxic effect of test compounds. There are many endpoints depending on the uptake and release (e.g. cation, anion, glucose, chemical, enzymes). Creative Bioarray offers nephrotoxicity assays for all small molecule formulations such as pharmaceuticals, industrial chemicals and consumer products.
Creative Bioarray's experts are capable of designing custom assays to meet the needs of our clients. Please feel free to contact us to learn more about our abilities to screen for drug toxicity. We will do our best to help you achieve your goals.